| abstract |
The present invention provides pharmaceutical compositions comprising LncRNA HCG18 inhibitors. The present invention fully reveals the function of LncRNA HCG18 in prostate cancer cells and the target genes regulated by it, and clarifies the new mechanism of LncRNA HCG18 regulating prostate cancer. The present invention conducts in-depth research on the specific mechanism of LncRNA HCG18 in the process of prostate cancer occurrence, development, migration, invasion, apoptosis, etc. It is confirmed that miR-23a is the target gene of LncRNA HCG18, and the effect of miR-23a on the downstream of LncRNA HCG18 is determined. Effects of protein GLS and LDH. In addition, the present invention conducts an in-depth study on the mechanism of LncRNA HCG18 and miR-23a involved in regulating the energy metabolism of prostate cancer cells, and clarifies the mechanism of the occurrence and development of prostate cancer. Sufficient theoretical basis provides new ideas for later-stage related drug development, clinical diagnosis and treatment, and has great social significance and market prospects. |